ERBB2 and cancer: In the context of cancer immunotherapy, the capability of activated γδ T cells to cross-present TAAs to αβ T cells could be further boosted through the “licensing” pathway (60, 187) by using therapeutic monoclonal antibodies against tumor cells, e.g., rituximab (anti-CD20) and trastuzumab (anti-HER2/neu) (145, 188, 189).